Results 211 to 220 of about 7,975,634 (337)

Retraction: PKCε activation restores loss of PKCε, manganese superoxide dismutase, vascular endothelial growth factor, and microvessels in aged and Alzheimer's disease hippocampus. [PDF]

Front Aging Neurosci
Frontiers Editorial Office.
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Chronic endometritis in women with recurrent pregnancy loss and recurrent implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in diagnosis.

Fertility and Sterility, 2016
P. Bouet, H. El Hachem, É. Monceau, G. Gariépy, I. Kadoch, C. Sylvestre   +5 more
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

[Retracted] Epithelial cell adhesion molecule is overexpressed in hypopharyngeal carcinoma and suppresses the metastasis and proliferation of the disease when downregulated. [PDF]

Oncol Lett
Mu Y, Sa N, Yu L, Lu S, Wang H, Xu W.
europepmc   +1 more source

From Dave\u27s Home Office [PDF]

, 1996
Sanford, Jim
core   +1 more source

Prisoners' perspectives on the transition from the prison to the community: Implications for settings-based health promotion [PDF]

, 2013
Artazcoz L, Boyatzis RE, Corcoran N, Crotty M, Department of Health, Dooris M, Dooris M, Evangelou M, Farrall S, Gill P, Jacobi JV, James Woodall, Jane South, King RD, King RD, Knepper P, Leech M, Metcalf H, Ministry of Justice, Ministry of Justice, Mitchell C, Naidoo J, Noaks L, Patton MQ, Prison Reform Trust, Prison Reform Trust, Rachael Dixey, Scriven A, Senior J, Smith C, Stewart D, WHO, Willmott D, Woodall J   +33 more
core   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Retraction: Linc00662 promotes tumorigenesis and progression by regulating miR-497-5p/AVL9 axis in colorectal cancer. [PDF]

Front Genet
Frontiers Editorial Office.
europepmc   +1 more source

A Standard Home Office Deduction [PDF]

, 2011
Connolly, Karen
core   +1 more source